Sage Journals: Discover world-class research

Abstract

Keywords

conflicts Food and Drug Administration funding sources off-label publication research

Get full access to this article

View all access options for this article.

References

American Academy of Orthopaedic Surgeons. Physician-directed use of medical products. Position statement 1177. Published 2008. Accessed October 24, 2025. https://www.aaos.org/globalassets/about/position-statements/1177-physician-directed-use-of-medical-products.pdf

Baird

. The January 6, 2025 final guidance on off-label use. Drug & Device Law. Published 2025. Accessed October 24, 2025. https://www.druganddevicelawblog.com

Beck

. Fourth Circuit affirms conviction of doctor for off-label use of medical device. Drug & Device Law. Published 2025. Accessed October 24, 2025. https://www.druganddevicelawblog.com

DrugPatentWatch. Unlocking hidden potential: common drugs with surprising off-label uses for market domination. DrugPatentWatch. Published 2025. Accessed October 24, 2025. https://www.drugpatentwatch.com

Code of Federal Regulations. Title 21, Part 822. Postmarket surveillance. Washington, DC: US Government Printing Office. Published 2025. Accessed October 24, 2025. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-822

Physician Weekly. Off-label prescribing liability: legal protection guide. Physicians Weekly. Published February 2025. Accessed October 24, 2025. https://www.physiciansweekly.com/post/avoiding-liability-in-off-label-prescribing

Riley

Barber

Kienle

, et al. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017;89:218-235.

Schulz

Altman

Moher

CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726-732.

Select Justice. Medtronic infuse bone graft lawsuit. Accessed October 24, 2025. Published October 2025. https://www.selectjustice.com/medtronic-infuse-bone-graft-lawsuit

10.

Syed

Dixson

Constantino

Regan

The law and practice of off-label prescribing and physician promotion. J Am Acad Psychiatry Law. 2021;49:53-59.

11.

U.S. Food and Drug Administration. Premarket approval (PMA) P000054: INFUSE bone graft. Silver Spring, MD: FDA; 2004. Accessed October 24, 2025. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P000054

12.

Van Norman

. Off-label use vs off-label marketing of drugs: part 1: off-label use—patient harms and prescriber responsibilities. JACC Basic Transl Sci. 2023;8(2):224-233.

13.

von Elm

Altman

Egger

, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808.